8-K: Inogen Reports Q2 2026 Results, Raises EBITDA Guidance

Inogen Inc. announced second quarter 2026 financial results, reporting $95.1 million in revenue and raising full-year adjusted EBITDA guidance to approximately $4.0 million.

Summary

• Inogen reported second quarter 2026 revenue of $95.1 million, a 3.0% increase year-over-year, driven by international sales growth.
• International revenue grew by 14.8% to $41.3 million.
• The company reported a GAAP net loss of $3.9 million for the quarter, an improvement from a $4.2 million net loss in the prior year.
• Adjusted EBITDA was positive at $2.4 million, up 15.2% year-over-year.
• Full-year 2026 revenue guidance is now projected between $355 million and $361 million.
• Full-year 2026 adjusted EBITDA guidance has been raised to approximately $4.0 million, a 48.1% increase from 2025.
• The Rove 6 portable oxygen concentrator was launched in Canada.
• Enrollment for the Simeox H SCOPE Study in China has been completed.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a cautiously optimistic report, with revenue growth and improved EBITDA guidance, but persistent net losses and a decline in U.S. rental patients indicate areas needing attention.

Positives

• Total revenue increased by 3.0% year-over-year to $95.1 million.
• International revenue showed strong growth of 14.8% to $41.3 million.
• GAAP net loss improved to $3.9 million from $4.2 million in the prior year.
• Positive adjusted EBITDA of $2.4 million was achieved, a 15.2% increase year-over-year.
• Operating cash flow was positive at $2.9 million for the quarter.
• Full-year adjusted EBITDA guidance was raised to approximately $4.0 million.
• Full-year revenue guidance was updated to a range of $355 million to $361 million.
• Gross margin improved to 45.5% from 44.8% in the prior year.

Negatives

• U.S. sales and rentals remained below the prior-year period.
• Net rental patients decreased from 50,400 to 45,500 year-over-year.
• The company reported a GAAP net loss of $3.9 million for the second quarter.
• Basic and diluted net loss per share was $0.14 for the quarter.

Risks

• Market acceptance of its products.
• Competition in the respiratory care market.
• The company's sales, marketing, and distribution capabilities.
• Planned sales, marketing, and research and development activities.
• Risks associated with international operations.
• Continued U.S. sales channel mix shift impacting revenue.
• Timing impact of select international distributor inventory purchases.

Future Outlook

For the full year 2026, Inogen expects revenue in the range of $355 million to $361 million, representing approximately 3% growth at the midpoint. Full-year 2026 adjusted EBITDA guidance has been raised to approximately $4.0 million. Third quarter 2026 revenue is expected to be approximately in line with the third quarter of 2025.

Management Comments

• "Our second quarter results demonstrate continued demand for our products and validate the progress of our strategy to expand and diversify Inogen's respiratory care portfolio," said Kevin Smith, President and Chief Executive Officer.
• "We are building momentum through new product launches, gaining traction in key markets, and driving greater operating leverage across the business."
• "As we continue to execute against our strategic priorities, we are diligently prioritizing our investments to balance growth, profitability, and innovation to deliver long-term value for shareholders."

Industry Context

StockSavvy.ai notes that Inogen's performance, particularly the growth in international markets and the launch of new products like the Rove 6, aligns with broader trends in the medical technology sector favoring global expansion and product innovation in homecare respiratory solutions. However, the continued decline in U.S. rental patients suggests ongoing challenges in that specific segment of the market.

Management Changes

Stakeholder Impact

• Shareholders: Potential for increased long-term value due to raised EBITDA guidance and strategic growth initiatives, but ongoing net losses may temper immediate enthusiasm.
• Employees: The addition of a COO and focus on growth may create opportunities, but financial performance pressures could impact job security.
• Customers: Continued product innovation and international expansion aim to improve access to respiratory care solutions.
• Distributors: Growth in international markets and traction with U.S. distributors are positive indicators.

Next Steps

• Statistical analysis results for the Simeox H SCOPE Study in China are expected in the second half of 2026.
• Continued execution against strategic priorities to balance growth, profitability, and innovation.
• Further expansion of the respiratory care portfolio.
• Leveraging the addition of Andy Reding as Chief Operating Officer to support growth initiatives.

Key Dates

Recommendation

The company shows signs of recovery with revenue growth and improved EBITDA guidance, but the persistent net losses and decline in U.S. rental patients warrant a cautious approach. The positive international performance and new product launches are encouraging, but the overall financial health requires further stabilization before a more bullish stance can be taken.

Keywords

Inogen, Respiratory Products, Portable Oxygen Concentrator, Homecare, Medical Technology, Oxygen Therapy, Chronic Obstructive Pulmonary Disease, Financial Results